CHRONIC MYELOID LEUKAEMIA: EPIDEMIOLOGY DATA (2002–2007)
Abstract
BACKGROUND Chronic myeloid leukaemia (CML) is a rare clonal neoplastic disease of hematopoieticstem cells. Epidemiology data of CML patients in Slovenia are presented. METHODS Data about all new patients with CML in the period from 2002 to 2007 were obtained fromall Slovenian hospitals with haematological department. RESULTS 90 patients were studied during the period of 6 years. The incidence was 0.75/100,000 onaverage. 14 patients (15 %) died. Incidence in male population was 4 % higher as infemale population. The patient population (average age 50.6 in males and 59.1 in femalesat the diagnosis of CML, respectively) was distributed also according to Slovenian statistical regions. The majority of patients was identified in the chronic phase of disease (83 %),being treated in recent years with imatinib (up to 85 % in 2007). CONCLUSIONS The incidence, as well as the average age of the patients with CML in Slovenia is lowercompared with data from the literature. The majority of patients are identified in earlystage of the disease and are treated in accordance with current guidelinesDownloads
Downloads
Published
Issue
Section
License
The Author transfers to the Publisher (Slovenian Medical Association) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Slovenian Medical Association) has the right to transfer the rights of acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
